Hamilton, Fergus
Pedersen, Kasper Mønsted
Ghazal, Peter
Nordestgaard, Børge Grønne
Smith, George Davey
Article History
Received: 25 April 2023
Accepted: 24 July 2023
First Online: 9 October 2023
Declarations
:
: This study was performed under the UK Biobank application number 30418. UK Biobank was ethically approved by the North West Multi-centre Research Ethics Committee (MREC). The FinnGen study is approved by the THL (Approval No. THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, and THL/1721/5.05.00/2019), the Digital and Population Data Service Agency (VRK43431/2017-3, VRK/6909/2018-3, and VRK/4415/2019-3), the Social Insurance Institution (KELA) (KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, and KELA 98/522/2019), and Statistics Finland (TK-53-1041-17).
: GDS reports Scientific Advisory Board Membership for Relation Therapeutics and Insitro. PG reports Founder and non-executive director of Fios Genomics Ltd and member of the development board of Sepsis Trust UK Ltd without renumeration. BGN reports consultancies/talks for AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott, Silence Therapeutics, and Ultragenyx. FH and KMP have nothing to declare.